EVAX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EV

Mkt Cap

$25.6M

Volume

73.39K

Next Earnings

November 19th

Loading chart

EV

EVAXEvaxion A/S American Depositary Share

EVAX

Pay with—

Available Balance0.00

EV

Mkt Cap

$25.5M

Volume

73.39K

Next Earnings

November 19th

Chart Financials Earnings News About Insider Filings

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual MeetingEvaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed.GlobeNewswire Inc. · Oct 2, 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1Evaxion announced new preclinical data supporting its multi-component cytomegalovirus (CMV) vaccine candidate EVX-V1, which combines AI-discovered antigens with optimized established antigens. The data demonstrates potential to improve control of acute infection, latency, and viral reactivation. EVX-V1 represents a scalable strategy for rational vaccine development across herpesviruses, addressing a significant unmet medical need as no CMV vaccine is currently licensed despite affecting 60-70% of adults in developed countries.GlobeNewswire Inc. · Jul 12, 2026

Evaxion receives Prix Galien UK Award for Best digital health solutionEvaxion A/S received the 2026 Prix Galien UK Award for Best Digital Health Solution for its AI-Immunology™ platform, which uses artificial intelligence to develop novel vaccine candidates for cancer and infectious diseases. This marks the company's second recognition from the Galien Prix Foundation in less than a year, validating the platform's capabilities in vaccine target discovery and development.GlobeNewswire Inc. · Jun 12, 2026

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemiaEvaxion announced positive preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). The vaccine successfully expresses and secretes in human cells, drives specific immune responses across different human immune profiles, and induces targeted cell-killing. The company is preparing regulatory filings for clinical testing and will present the data at the European Hematology Association Congress in Stockholm on June 13, 2026.GlobeNewswire Inc. · Jun 11, 2026

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating OfficerEvaxion A/S announced the promotion of Birgitte Rønø to serve as both Chief Scientific Officer and Chief Operating Officer, reflecting her extensive contributions to the company's operations and scientific expertise. The move is intended to enhance external engagement and strategy execution while strengthening the company's ability to communicate its AI-Immunology™ platform capabilities to partners and investors.GlobeNewswire Inc. · Apr 27, 2026

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastomaEvaxion announced data demonstrating its AI-Immunology platform can identify endogenous retrovirus (ERV)-derived antigens for glioblastoma vaccine design, in collaboration with Duke University. The findings show ERVs as a novel antigen source that could overcome limitations from low mutational burden in brain cancer, with results to be presented at the AACR Annual Meeting in April 2026.GlobeNewswire Inc. · Apr 17, 2026

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01Evaxion has completed the one-year extension of its phase 2 trial for EVX-01, a personalized cancer vaccine for advanced melanoma. The trial demonstrated a 75% Objective Response Rate with 92% of patients still responding at two-year follow-up. Three-year clinical efficacy data is expected in the second half of 2026.GlobeNewswire Inc. · Apr 7, 2026

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine CongressEvaxion has developed novel polio vaccine design concepts using its AI-Immunology™ platform in collaboration with the Gates Foundation. The company will present these concepts, along with data from its EVX-V1 cytomegalovirus vaccine program, at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026. The new polio vaccine designs aim to combine the strengths of existing vaccines while addressing their individual shortcomings.GlobeNewswire Inc. · Mar 30, 2026

Notice to convene Evaxion’s Annual General MeetingEvaxion A/S, a clinical-stage TechBio company, announced its Annual General Meeting scheduled for April 16, 2026, at its Copenhagen offices. The company continues developing novel vaccines using its AI-Immunology™ platform for cancer and infectious diseases, with a clinical pipeline of personalized and off-the-shelf vaccine candidates.GlobeNewswire Inc. · Mar 19, 2026

Evaxion to announce business update and full year 2025 financial results on March 5, 2026Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company, will report its full year 2025 financial results and provide a business update on March 5, 2026. The company will host a conference call and webcast at 14:30 CET/08:30 EST to present results and discuss its AI-Immunology™ platform development for cancer vaccines, infectious disease vaccines, and newly expanded autoimmune disease applications.GlobeNewswire Inc. · Mar 2, 2026

to start trading

EV

EVAXEvaxion A/S American Depositary Share

EVAX

Pay with—

Available Balance0.00

Your PositionYou don't own any EVAX yet.

Related Tickers

Earnings